256 related articles for article (PubMed ID: 27742006)
1. Liver Fibrosis Reversion After Suppression of Hepatitis B Virus.
Rockey DC
Clin Liver Dis; 2016 Nov; 20(4):667-679. PubMed ID: 27742006
[TBL] [Abstract][Full Text] [Related]
2. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.
Okada M; Enomoto M; Kawada N; Nguyen MH
Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1095-1104. PubMed ID: 28752768
[TBL] [Abstract][Full Text] [Related]
3. Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure.
Zeisel MB; Lucifora J; Mason WS; Sureau C; Beck J; Levrero M; Kann M; Knolle PA; Benkirane M; Durantel D; Michel ML; Autran B; Cosset FL; Strick-Marchand H; Trépo C; Kao JH; Carrat F; Lacombe K; Schinazi RF; Barré-Sinoussi F; Delfraissy JF; Zoulim F
Gut; 2015 Aug; 64(8):1314-26. PubMed ID: 25670809
[TBL] [Abstract][Full Text] [Related]
4. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs.
Brown A; Goodman Z
Expert Rev Gastroenterol Hepatol; 2012 Apr; 6(2):187-98. PubMed ID: 22375524
[TBL] [Abstract][Full Text] [Related]
6. Treatment of HBV-related cirrhosis.
Vallet-Pichard A; Mallet V; Costentin CE; Pol S
Expert Rev Anti Infect Ther; 2009 Jun; 7(5):527-35. PubMed ID: 19485793
[TBL] [Abstract][Full Text] [Related]
7. Impact of HBV therapy on the incidence of hepatocellular carcinoma.
Triolo M; Della Corte C; Colombo M
Liver Int; 2014 Feb; 34 Suppl 1():139-45. PubMed ID: 24373091
[TBL] [Abstract][Full Text] [Related]
8. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
9. [Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis].
Xu Y; Wang JB; Xu J; Jiao J; Zhang YG; Ji SW; Zhao P; Guo HH; Li Y; Zhou CY
Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):109-12. PubMed ID: 20196949
[TBL] [Abstract][Full Text] [Related]
10. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
Lampertico P; Invernizzi F; Viganò M; Loglio A; Mangia G; Facchetti F; Primignani M; Jovani M; Iavarone M; Fraquelli M; Casazza G; de Franchis R; Colombo M
J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
[TBL] [Abstract][Full Text] [Related]
11. Regression of esophageal varices during entecavir treatment in patients with hepatitis-B-virus-related liver cirrhosis.
Jwa HY; Cho YK; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU; Kim BS; Lee BW; Song BC
Clin Mol Hepatol; 2016 Mar; 22(1):183-7. PubMed ID: 27044771
[TBL] [Abstract][Full Text] [Related]
12. NIH consensus development statement on management of hepatitis B.
Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
[TBL] [Abstract][Full Text] [Related]
13. Review article: current antiviral therapy of chronic hepatitis B.
Ayoub WS; Keeffe EB
Aliment Pharmacol Ther; 2011 Nov; 34(10):1145-58. PubMed ID: 21978243
[TBL] [Abstract][Full Text] [Related]
14. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.
Wang JL; Du XF; Chen SL; Yu YQ; Wang J; Hu XQ; Shao LY; Chen JZ; Weng XH; Zhang WH
World J Gastroenterol; 2015 Aug; 21(32):9598-606. PubMed ID: 26327767
[TBL] [Abstract][Full Text] [Related]
15. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
[TBL] [Abstract][Full Text] [Related]
16. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.
Eun JR; Lee HJ; Kim TN; Lee KS
J Hepatol; 2010 Jul; 53(1):118-25. PubMed ID: 20471129
[TBL] [Abstract][Full Text] [Related]
17. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.
Wang PC; Wei TY; Tseng TC; Lin HH; Wang CC
Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):946-950. PubMed ID: 28538267
[TBL] [Abstract][Full Text] [Related]
18. Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations.
Yuen MF; Ahn SH; Chen DS; Chen PJ; Dusheiko GM; Hou JL; Maddrey WC; Mizokami M; Seto WK; Zoulim F; Lai CL
J Clin Gastroenterol; 2016 Apr; 50(4):286-94. PubMed ID: 26840752
[TBL] [Abstract][Full Text] [Related]
19. [New insight for HBV DNA and HBsAg quantitation during antiviral therapy in patients with chronic hepatitis B].
Cho YK; Song BC
Korean J Gastroenterol; 2011 Mar; 57(3):144-9. PubMed ID: 21519161
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy.
Liaw YF
Antivir Ther; 2006; 11(6):669-79. PubMed ID: 17310811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
